Skip to main content

Pfizer to Use Sigma-Aldrich's ddRNAi Gene Silencing Tech

NEW YORK (GenomeWeb News) — Sigma-Aldrich today said it has granted Pfizer non-exclusive rights to its DNA-directed RNAi technology.
 
The agreement will allow Pfizer’s to use Sigma’s ddRNAi at any of its worldwide operations, Sigma said.
 
Sigma said it has exclusively licensed ddRNAi applications from Australian company Benitec and Australia’s Commonwealth Scientific and Industrial Research Organization.  
 
Financial terms of the agreement were not released.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.